NCT00092560已完成3 期
Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 587
- 主要终点
- Plasma LDL-C vs. fenofibrate for 12 weeks.
研究概览
简要总结
The purpose of this study is to evaluate the cholesterol lowering effectiveness and safety of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).
详细描述
The duration of treatment is 18 weeks.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •High cholesterol and high triglycerides
排除标准
- •Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study
结局指标
主要结局
Plasma LDL-C vs. fenofibrate for 12 weeks.
次要结局
- All plasma lipid parameters vs. ezetimibe; all non-LDL lipid parameters vs. fenofibrate; safety and tolerability.
研究者
相似试验
已完成
3 期
Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)HypercholesterolemiaHypertriglyceridemiaNCT00092573Organon and Co576
招募中
不适用
Safety Study of Fenofibrate During PregnancySevere Hypertriglyceridemia During PregnancyNCT05883865First People's Hospital of Hangzhou250
撤回
1 期
Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033ObesityNCT00376285Pfizer
已完成
3 期
A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)HypercholesterolemiaHyperlipidemiaHypertriglyceridemiaNCT00093899Organon and Co611
已完成
不适用
Functional evaluation of cholesterol level reduction in humansHealthy adultJPRN-UMIN000048222EP Mediate Co., Ltd.60